News and Press Releases
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
Upfront fees and near-term development milestone payments totaling up to $7.5 million Potential sales milestones of $180 million or more in first 10 years of commercialization Royalties equaling 25% of...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: September 15, 2025
Celltrion opens new UK headquarters in Uxbridge, UK
New office located in the heart of Uxbridge underscores Celltrion’s long-term business commitment in the UK 17 June 2025 -- London, UK -- Celltrion UK has officially opened its new...
Category: Clinical Trials, Drug Discovery, Manufacturing and Packing, Other, Pharmaceutical
Posted: June 17, 2025
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: April 18, 2025
The Charter Building, Vine Street, Uxbridge, Middlesex, United Kingdom, UB8 1JG
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adults with elevated eosinophils Approval marks the first new treatment...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: March 28, 2025
Exclusive UniSafe® distribution agreement between Owen Mumford and NIPRO exceeds expectations in Japan with new biosimilar launch
6 December 2024 - Oxford, UK – Owen Mumford, a global leader in medical devices, is pleased to announce that its exclusive agreement with Osaka-based NIPRO CORPORATION (NIPRO) to distribute...
Category: Drug Delivery, Manufacturing and Packing
Posted: December 6, 2024
ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement
License agreement provides Université de Montréal access to CRISPR gene editing technology for use across its platform services 1 October 2024 -- Dublin, Ireland, and Montreal, Canada -- ERS Genomics...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: October 1, 2024
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
Recommendation based on a phase 3 study showing a significantly greater proportion of children on Dupixent achieved histological remission, compared to placebo, consistent with improvements seen in adults and adolescents...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 20, 2024
The Charter Building, Vine Street, Uxbridge, Middlesex, United Kingdom, UB8 1JG
Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer
Results from the pivotal Phase III ARANOTE trial evaluating darolutamide plus androgen deprivation therapy (ADT) showed a statistically significant increase in radiological progression-free survival (rPFS) compared to placebo plus ADT...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 16, 2024
Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz
Just – Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars Additional biosimilars potentially to be added to Sandoz development pipeline Further guarantees for Sandoz long-term...
Category: BioManufacturing, Biotechnology
Posted: July 10, 2024
Just – Evotec Biologics, Inc. 401 Terry Avenue North Seattle, WA 98109, US
Formycon receives FDA approval for FYB203/ AHZANTIVE) (aflibercept-mrbb), a biosimilar to Eylea
1 July 2024, Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) and its licencing partnerKlinge Biopharma GmbH ("Klinge") jointly announce that the U.S. Food and Drug Administration ("FDA")approved FYB203/AHZANTIVE (aflibercept-mrbb),...
Category: Pharmaceutical
Posted: July 1, 2024
Formycon reports on the results of the annual general meeting
Management provides detailed report on financial year 2023 and current company performance. Shareholders approve all agenda items and formally approve the acts of the members of the management board and...
Category: BioManufacturing
Posted: June 13, 2024
Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe
30 November 2023 -- Bengaluru, India -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, today announced that the integration of the Viatris’ biosimilars business in 31 European countries has been successfully...
Category: Pharmaceutical
Posted: November 30, 2023
Biocon House, Semicon Park Electronics City, Phase – II, Hosur Road Bengaluru 560100, Karnataka, India
AskBio Announces First Patient Dosed in Phase 1/Phase 2 Trial of AB-1003 Gene Therapy for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
Gene therapy developed to restore FKRP enzyme activity, primarily inside muscle cells, for the treatment of LGMD2I/R9 3 August 2023 -- North Carolina, US -- Asklepios BioPharmaceutical, Inc. (AskBio), a...
Category: Clinical Trials
Posted: August 3, 2023
Roslin Innovation Centre Easter Bush Campus Edinburgh, Scotland EH25 9RG
